Duchenne muscular dystrophy (DMD) is one of the most common and severe forms of muscular dystrophy, affecting approximately 1 in every 3,500 male births worldwide. Caused by mutations in the gene responsible for producing dystrophin — a protein essential for muscle cell integrity — DMD leads to progressive muscle weakness that typically begins in early childhood and worsens over time.

For pharmaceutical companies, clinical research organisations (CROs), and procurement teams, DMD represents a fast-evolving therapeutic category. The number of approved duchenne muscular dystrophy medicines has grown significantly in recent years, spanning corticosteroids, exon-skipping therapies, HDAC inhibitors, and gene therapy. Understanding the treatment landscape and knowing how to source these medicines reliably is now a critical capability for any organisation involved in rare disease supply, clinical trial logistics, or named patient programmes.

This guide breaks down the current duchenne muscular dystrophy treatment options, the approved medicines by drug class, and the sourcing considerations that B2B buyers should factor into their procurement strategy.

The DMD Treatment Landscape in 2026

The therapeutic landscape for DMD has transformed over the past decade. Where treatment was once limited to conventional corticosteroids like prednisone, the FDA has now approved multiple targeted therapies that address different aspects of the disease. These treatments fall into four main categories:

• Corticosteroids remain the standard of care for managing inflammation and slowing muscle decline. Newer-generation corticosteroids such as vamorolone offer improved side-effect profiles compared to traditional options like prednisone and deflazacort.
• Exon-skipping therapies are antisense oligonucleotides (ASOs) designed for patients with specific genetic mutations. They work by skipping over faulty sections of the dystrophin gene, allowing muscle cells to produce a shorter but partially functional form of dystrophin.
• HDAC inhibitors target the overactivity of histone deacetylase enzymes, which contributes to muscle damage in DMD. By inhibiting these enzymes, this class slows muscle deterioration, reduces tissue necrosis, and supports muscle mass preservation.
• Gene therapy aims to deliver a functional version of the dystrophin gene directly to muscle cells, with the goal of producing enough dystrophin protein to delay or stabilise disease progression.

Each category serves a different clinical need, and many patients receive combination approaches. For procurement teams, this means sourcing across multiple drug classes, each with its own storage, handling, and regulatory requirements.

FDA-Approved Duchenne Muscular Dystrophy Medicines

The tables below summarise the currently approved duchenne muscular dystrophy medicines, organised by drug class.

Corticosteroids

Medicine	Active Ingredient	Approved Age	Key Notes
Agamree	Vamorolone	2 years and older	Next-generation corticosteroid with fewer bone and metabolic side effects than traditional steroids. FDA and EMA approved in 2023.
Emflaza	Deflazacort	2 years and older	FDA-approved glucocorticoid for DMD. Generic versions available in tablets and oral suspension.
Jaythari	Deflazacort	5 years and older	Deflazacort tablet formulation offering an alternative access option.
Prednisone	Prednisone	Varies	Long-established corticosteroid widely used in DMD management.

Agamree (vamorolone) deserves particular attention from procurement teams. Approved by both the FDA and EMA in late 2023, vamorolone is the first duchenne muscular dystrophy medicine approved simultaneously by both agencies. It acts through the glucocorticoid receptor to reduce inflammation while demonstrating a more favourable safety profile on bone health, behaviour, and metabolic markers compared to older corticosteroids. For CROs running trials that require a comparator drug in the corticosteroid class, Agamree is increasingly relevant.

Emflaza (deflazacort) has been the standard glucocorticoid for DMD since its FDA approval in 2017, with a label expansion to patients as young as 2 years in 2019. Deflazacort is also available through multiple generic manufacturers, making it one of the more accessible duchenne muscular dystrophy treatment options for global supply.

Exon-Skipping Therapies (Antisense Oligonucleotides)

Medicine	Active Ingredient	Target Mutation	FDA Approval
Exondys 51	Eteplirsen	Exon 51 skipping	2016
Viltepso	Viltolarsen	Exon 53 skipping	2020
Vyondys 53	Golodirsen	Exon 53 skipping	2019
Amondys 45	Casimersen	Exon 45 skipping	2021

Exon-skipping therapies are mutation-specific, meaning each medicine is indicated only for patients whose DMD gene mutation is amenable to skipping of a particular exon. Approximately 30% of DMD patients are eligible for one of the currently approved exon-skipping therapies.

HDAC Inhibitor

Medicine	Active Ingredient	Approved Age	FDA Approval
Duvyzat	Givinostat	6 years and older	March 2024

Duvyzat (givinostat) represents a newer class of duchenne muscular dystrophy treatment. Unlike exon-skipping therapies, givinostat works across all genetic variants of DMD, making it applicable to a broader patient population. It is administered as an oral suspension twice daily with food. The phase 3 EPIDYS trial demonstrated statistically significant improvement in the four-stair climb assessment compared to placebo.

Gene Therapy

Medicine	Active Ingredient	Approved Age	FDA Approval
Elevidys	Delandistrogene moxeparvovec-rokl	4 years and older	2023 (accelerated), 2024 (expanded)

Elevidys is the first gene therapy approved for DMD. It delivers a shortened version of the dystrophin gene to muscle cells via an adeno-associated virus (AAV) vector and is administered as a one-time intravenous infusion. Elevidys is primarily relevant for specialised treatment centres and clinical research programmes rather than standard pharmaceutical supply chains, given its complex manufacturing and administration requirements.

Sourcing Challenges for DMD Medicines

Duchenne muscular dystrophy medicines present specific procurement challenges that set them apart from standard pharmaceutical supply:

• Orphan drug access. Most DMD therapies carry orphan drug designation, which means limited manufacturing volumes and restricted distribution channels. Procurement teams often face long lead times and allocation constraints, particularly for newer therapies like Agamree and Duvyzat.
• Regulatory complexity across markets. Approval timelines and availability vary significantly by country. A medicine approved by the FDA may not yet have EMA or local regulatory clearance, creating demand for named patient supply or emergency import pathways.
• Cold chain and storage requirements. Injectable therapies such as Exondys 51 require refrigerated storage between 2°C and 8°C and protection from light. Any break in the cold chain during transit compromises product integrity.
• Clinical trial and comparator drug needs. CROs and sponsors conducting DMD trials frequently need comparator drugs, reference listed drugs (RLDs), and specific formulations that are difficult to procure through standard distribution.
• Named patient supply. In markets where a DMD medicine is not yet commercially available, named patient supply (also called compassionate use or managed access) provides a legal pathway for individual patients to receive treatment.

GNH India: Your Partner for DMD Medicine Supply

GNH India is a WHO-GSDP certified global pharmaceutical supplier with dedicated capabilities in orphan drug supply, named patient programmes, and clinical trials supply. With shipping to over 180 countries and a catalogue of more than 6,700 pharmaceutical products, GNH India supports procurement teams, CROs, and pharmaceutical companies in sourcing hard-to-find medicines, including treatments for duchenne muscular dystrophy.

DMD medicines available through GNH India include:

• Agamree (Vamorolone) 40mg/ml Suspension — the next-generation corticosteroid for DMD, sourced from Italy (Catalyst Pharmaceuticals).
• Exondys 51 (Eteplirsen) 500mg/10ml Vials — the first approved exon-skipping therapy for DMD, with validated cold chain logistics.
• Emflaza (Deflazacort) Tablets — the established glucocorticoid for DMD in multiple strengths, including branded and generic options.

All operations are backed by ISO 9001:2015 certification, WHO Good Storage and Distribution Practices (GSDP) compliance, and licensing from FDA Maharashtra and DGFT.